Filing Flows › Health Care › Avalo Therapeutics (AVTX)

Avalo Therapeutics (AVTX) earnings and revenue breakdown

Latest: Q4 2025 · 10-K filed Mar 23, 2026 · Avalo Therapeutics (AVTX) Q4 2025 earnings results →

Q4 2025 Revenue down 69% year over year to $59K

Avalo Therapeutics made $59K in Q4 2025 (-69% Y/Y). Operating margin n/m, net loss $13.7M. See where every dollar goes — costs, profit and cash — as a Sankey from the 10-K filed Mar 23, 2026.

Revenue$59K

Year over year-69%

Operating marginn/m

Net earnings−$13.7M

Operating cash flow−$14.2M

Drawing the Sankey…

Open the interactive Sankey → click any line for what the company wrote about it, compare Y/Y and Q/Q, export as PNG or PDF

What changed this quarter

Revenue was $59K in Q4 2025, down 69% year over year.

Operating costs exceeded revenue by $19.7M, an operating margin of -33461.0%. Total costs grew 47% against a revenue fall of 69%. The fastest-growing cost line was Research & development (+62%). The quarter ended with a net loss of $13.7M. Non-operating items added $6.2M, -45% of pre-tax earnings, so the bottom line overstates operating performance.

Operating cash flow was −$14.2M. Non-cash charges added back $16K of depreciation and amortization and $4.5M of share-based compensation. Working capital and other items used $5.0M.

Quarterly history

Quarter	Form	Filed	Revenue	Y/Y	Op. margin	Net earnings	Op. cash flow
Q4 2025	10-K	Mar 23, 2026	$59K	-69%	n/m	−$13.7M	−$14.2M
Q4 2024	10-K	Mar 20, 2025	$192K	-66%	n/m	−$35.3M	−$15.0M

Charts

From the cash-flow statement as filed (SEC XBRL). Cash is fungible: the bars do not say which dollar paid for what.

Latest (Q3 2026): Net income −$18.9M, Operating cash flow −$11.5M.

+16997.1% since FY2022: more shares outstanding (issuance, stock pay); earlier years scaled for the 2-for-1 split before FY2025.

Pharmaceutical Preparations; dot size is quarterly revenue; dashed lines are the industry's medians.